Keyphrases
Relapsed or Refractory
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
B-cell Lymphoma
100%
Chimeric Antigen Receptor T-cell Therapy
100%
Mosunetuzumab
100%
Bispecific Antibody
30%
BsAb
30%
CD8+ T Cells
20%
Optimal Timing
20%
Multiple Comparisons
10%
Clinical Data
10%
Paired Samples
10%
Previously Treated
10%
Lymphocytes
10%
Blood Samples
10%
Median Time
10%
CD4 Cells
10%
T Cell Antigen Receptor
10%
Non-responders
10%
CD20
10%
CD19
10%
Phase 1/2 Study
10%
CD3 Bispecific
10%
Lymphocytes T
10%
Neuroscience
Cell Therapy
100%
T Cell
100%
B Cell
100%
Chimeric Antigen Receptor
100%
Mosunetuzumab
100%
Bispecific Antibody
27%
CD8
18%
Transgene
18%
Lymphocyte
18%
CD4
9%
T Lymphocyte Receptor
9%
CD19
9%
CD20
9%
CD3 Antigen
9%
Immunology and Microbiology
B Cell
100%
Chimeric Antigen Receptor
100%
Chimeric Antigen Receptor T-Cell Therapy
100%
Mosunetuzumab
100%
Bispecific Antibody
30%
CD8
20%
T Cell
20%
Transgene
20%
Lymphocyte
20%
CD4
10%
CD20
10%
CD19
10%
CD3 Antigen
10%
Medicine and Dentistry
B-Cell Lymphoma
100%
Chimeric Antigen Receptor T-Cell Immunotherapy
100%
Chimeric Antigen Receptor
100%
Mosunetuzumab
100%
Bispecific Antibody
30%
CD8 Antigen
20%
Transgene
20%
Lymphocyte
20%
Biological Marker
10%
T Cell
10%
T Lymphocyte Receptor
10%
CD20
10%
CD3 Antigen
10%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
B Cell
100%
Chimeric Antigen Receptor
100%
Transgene
18%
CD8
18%
Lymphocyte
18%
CD4
9%
CD19
9%
CD20
9%